Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab + mLSG15 in Untreated CCR4+ Adult T-cell Leukemia-Lymphoma
NCT01173887Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2010
- Primary completion
- Apr 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mogamulizumab in adult T-cell leukemia-lymphoma (ATLL), sponsored by Kyowa Kirin. Primary endpoint: Complete Response Rate. Started Jul 2010; status: completed.
02
Drugs
mogamulizumab
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT01173887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01173887.